Please Wait a Moment
X

Articles

14Feb

CTS to Implement Donor HLA testing on the Stratec Gemini Instrument

14 Feb, 2019 | Return|

On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation. 

Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.

 

 

 

 

Related

COVID-19 Antibody Testing Frequently Asked Questions

The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...

Read More >

CTS to Implement Licensed Babesia testing

In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols  ...

Read More >

CTS Dallas and Phoenix Labs Implements WNV Testing on the Panther

CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...

Read More >

CTS to Implement the Grifols Procleix Ultrio Elite Assay Beginning June 1, 2020

Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...

Read More >

CTS Tampa Implementation date change for Ultrio Elite

CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...

Read More >

Seasonal Monitoring for WNV to begin June 1, 2020

Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...

Read More >